Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents - PubMed (original) (raw)
Review
. 2003 Sep 29;22(42):6598-608.
doi: 10.1038/sj.onc.1206758.
Affiliations
- PMID: 14528285
- DOI: 10.1038/sj.onc.1206758
Review
Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents
Brian J Nickoloff et al. Oncogene. 2003.
Abstract
Notch signaling controls cell fate decisions including during development and stem cell renewal and differentiation in many postnatal tissues. Increasing evidence suggests that the Notch signaling network is frequently deregulated in human malignancies and that genetic or pharmacological manipulation of Notch signaling is a novel potential strategy for the treatment of human neoplasms. This review article summarizes the most recent preclinical and clinical evidence linking Notch signaling to cancer, delineates questions that remain unanswered and explores potential biopharmacological strategies to manipulate Notch signaling in vivo.
Similar articles
- Notch signaling as a target in multimodality cancer therapy.
Jang MS, Zlobin A, Kast WM, Miele L. Jang MS, et al. Curr Opin Mol Ther. 2000 Feb;2(1):55-65. Curr Opin Mol Ther. 2000. PMID: 11249652 Review. - Arbiter of differentiation and death: Notch signaling meets apoptosis.
Miele L, Osborne B. Miele L, et al. J Cell Physiol. 1999 Dec;181(3):393-409. doi: 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6. J Cell Physiol. 1999. PMID: 10528225 Review. - Notch signaling in the hematopoietic system.
Sandy AR, Maillard I. Sandy AR, et al. Expert Opin Biol Ther. 2009 Nov;9(11):1383-98. doi: 10.1517/14712590903260777. Expert Opin Biol Ther. 2009. PMID: 19743891 Review. - Exploitation of the Notch signaling pathway as a novel target for cancer therapy.
Wang Z, Li Y, Banerjee S, Sarkar FH. Wang Z, et al. Anticancer Res. 2008 Nov-Dec;28(6A):3621-30. Anticancer Res. 2008. PMID: 19189643 Review. - The role of Notch in tumorigenesis: oncogene or tumour suppressor?
Radtke F, Raj K. Radtke F, et al. Nat Rev Cancer. 2003 Oct;3(10):756-67. doi: 10.1038/nrc1186. Nat Rev Cancer. 2003. PMID: 14570040 Review.
Cited by
- OCT4's role and mechanism underlying oral squamous cell carcinoma.
Dai Y, Wu Z, Chen Y, Ye X, Wang C, Zhu H. Dai Y, et al. J Zhejiang Univ Sci B. 2023 Sept 15;24(9):796-806. doi: 10.1631/jzus.B2200602. J Zhejiang Univ Sci B. 2023. PMID: 37701956 Free PMC article. - Innovative Therapeutic Approaches for the Treatment of the Ocular Morbidities in Patients with EEC Syndrome.
Barbaro V, Bonelli F, Ferrari S, La Vella G, Di Iorio E. Barbaro V, et al. Cells. 2023 Feb 2;12(3):495. doi: 10.3390/cells12030495. Cells. 2023. PMID: 36766837 Free PMC article. Review. - Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.
Saha T, Lukong KE. Saha T, et al. Front Oncol. 2022 Mar 21;12:856974. doi: 10.3389/fonc.2022.856974. eCollection 2022. Front Oncol. 2022. PMID: 35392236 Free PMC article. Review. - DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment.
Kumari M, Krishnamurthy PT, Pinduprolu SKSS, Sola P. Kumari M, et al. Adv Pharm Bull. 2021 Sep;11(4):618-623. doi: 10.34172/apb.2021.070. Epub 2020 Oct 19. Adv Pharm Bull. 2021. PMID: 34888208 Free PMC article. Review. - DAPT suppresses proliferation and migration of hepatocellular carcinoma by regulating the extracellular matrix and inhibiting the Hes1/PTEN/AKT/mTOR signaling pathway.
Qiu K, Ma C, Lu L, Wang J, Chen B, Mao H, Wang Y, Wang H. Qiu K, et al. J Gastrointest Oncol. 2021 Jun;12(3):1101-1116. doi: 10.21037/jgo-21-235. J Gastrointest Oncol. 2021. PMID: 34295560 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources